Breakthrough in EGFR-Mutated NSCLC: Rybrevant Plus Lazcluze Extends Overall Survival

By Gina Shaw
The bispecific antibody amivantamab-vmjw (Rybrevant, Janssen/Johnson & Johnson) plus lazertinib (Lazcluze, Janssen/J&J) significantly extended overall survival (OS) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with certain epidermal growth factor receptor (EGFR) mutations, according to new top-line results from the phase 3 MARIPOSA study.